HUMAN RECOMBINANT P2Y2 RECEPTOR
MULTISCREEN™ DIVISION ARRESTED CELL LINE
1 vial (4 x 106) frozen cells
Sigma Freezing Medium (C-6164)
Expression vector containing full-length human P2Y2 cDNA (GenBank Accession Number NM_002564) with FLAG tag sequence at N-terminus
Liquid nitrogen upon receiving
Propagation Medium: DMEM, 10% FBS, 1 μg/mL puromycin
Stable for 1-2 days after thawing
Background: The P2Y2 receptor was the first of this family of receptors that can be fully activated by both ATP and UTP. P2Y2 receptors are present on all of the body’s mucosal surfaces, including the lungs, eyes, upper airways, mouth, vaginal tract and gastrointestinal tract. P2Y2 receptors have also been found on non-mucosal surfaces, such as the retinal pigment epithelium. Activation of P2Y2 has been shown to stimulate mucosal hydration and mucociliary clearance in the lungs and upper airways and induce secretion of therapeutically significant amounts of fluid and tear components to the ocular surface. Thus, P2Y2 receptors are therapeutic targets for treating serious disorders including cystic fibrosis, a fatal genetic disease, retinal detachment as well as dry eye disease.
Application: Functional assays
Figure 1. Dose-dependent calcium flux upon treatment with ligand, measured with MultiscreenTM Calcium 1.0 No Wash Assay Kit (Multispan MSCA01).
Kellerman et al. (2002) Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease. Adv Drug Deliv Rev 54:1463-1474.
Shaver (2001) P2Y receptors: biological advances and therapeutic opportunities. Curr Opin Drug Discov Devel 4(5): 665-70.
Sromek and Harden (1998) Agonist-induced internalization of the P2Y2 receptor. Mol Pharmacol 54:485-494.